Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Wednesday, July 23, 2025 1 min read
Key Takeaway: Nkarta, Inc. announced its participation in the H.C. Wainwright 'HCW@Home' Series, scheduled for July 30, 2025. The event will feature a fireside chat at 11:00 a.m. ET, and a webcast will be available for those unable to attend live. Nkarta is focused on developing engineered NK cell therapies for autoimmune diseases.
Price reaction · baseline $2.08 (2025-07-22 close) · hit pre-market · clean, no other NKTX news in the window
day 0 close · peak
+7.2%
day 1
+2.9%
day 3
+5.8%
Market Sentiment Analysis
POSITIVE FACTORS
Nkarta is actively participating in a prominent investor series.
The company is advancing innovative NK cell therapies.
The event provides a platform for investor engagement and information sharing.
Full Press Release Details
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series.
H.C Wainwright “HCW@Home with Nkarta, Inc.”July 30, 202511:00 a.m. ET – fireside chat
Register for the webcasthere. A simultaneous webcast of the event will also be available on the Investors section of Nkarta’s website,www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website atwww.nkartatx.com.